{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:10:54Z","timestamp":1793333454415,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002790","name":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["2018-06047"],"award-info":[{"award-number":["2018-06047"]}],"id":[{"id":"10.13039\/501100002790","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1038\/s41429-019-0221-9","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T04:02:29Z","timestamp":1565928149000},"page":"816-826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Development of a nebramine-cyclam conjugate as an antibacterial adjuvant to potentiate \u03b2-lactam antibiotics against multidrug-resistant P. aeruginosa"],"prefix":"10.1038","volume":"72","author":[{"given":"Derek","family":"Ammeter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1583-8562","authenticated-orcid":false,"given":"Temilolu","family":"Idowu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Zhanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-5519","authenticated-orcid":false,"given":"Frank","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,16]]},"reference":[{"key":"221_CR1","first-page":"25","volume":"6","author":"RJ Fair","year":"2014","unstructured":"Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Med Chem. 2014;6:25\u201364.","journal-title":"Perspect Med Chem"},{"key":"221_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1021\/acsinfecdis.5b00097","volume":"1","author":"HI Zgurskaya","year":"2015","unstructured":"Zgurskaya HI, Lopez CA, Gnanakaran S. Permeability barrier of gram-negative cell envelopes and approaches to bypass it. ACS Infect Dis. 2015;1:512\u201322.","journal-title":"ACS Infect Dis"},{"key":"221_CR3","doi-asserted-by":"publisher","first-page":"e00077","DOI":"10.1128\/CMR.00077-17","volume":"31","author":"R Domalaon","year":"2018","unstructured":"Domalaon R, Idowu T, Zhanel GG, Schweizer F. Antibiotic hybrids: the next generation of agents and adjuvants against gram-negative pathogens? Clin Microbiol Rev. 2018;31:e00077\u201317.","journal-title":"Clin Microbiol Rev"},{"key":"221_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1469-0691.2005.01305.x","volume":"12","author":"CY Wang","year":"2006","unstructured":"Wang CY, et al. Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes. Clin Microbiol Infect. 2006;12:63\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"221_CR5","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nature17042","volume":"529","author":"ED Brown","year":"2016","unstructured":"Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature . 2016;529:336\u201343.","journal-title":"Nature"},{"key":"221_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nature14098","volume":"517","author":"LL Ling","year":"2015","unstructured":"Ling LL, et al. A new antibiotic kills pathogens without detectable resistance. Nature . 2015;517:455\u20139.","journal-title":"Nature"},{"key":"221_CR7","doi-asserted-by":"publisher","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","volume":"6","author":"K Bush","year":"2016","unstructured":"Bush K, Bradford PA. \u03b2-lactams and \u03b2-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6:a025247.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"221_CR8","first-page":"1207","volume":"7","author":"B Thakuria","year":"2013","unstructured":"Thakuria B, Lahon K. The beta lactam antibiotics as an empirical therapy in a developing country: an update on their current status and recommendations to counter the resistance against them. J Clin Diagn Res. 2013;7:1207\u201314.","journal-title":"J Clin Diagn Res"},{"key":"221_CR9","first-page":"15","volume":"3","author":"G Meletis","year":"2016","unstructured":"Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3:15\u201321.","journal-title":"Ther Adv Infect Dis"},{"key":"221_CR10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1128\/CMR.00043-12","volume":"25","author":"L Fern\u00e1ndez","year":"2012","unstructured":"Fern\u00e1ndez L, Hancock REW. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev. 2012;25:661\u201381.","journal-title":"Clin Microbiol Rev"},{"key":"221_CR11","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.tim.2016.06.009","volume":"24","author":"GD Wright","year":"2016","unstructured":"Wright GD. Antibiotic adjuvants: rescuing antibiotics from resistance. Trends Microbiol. 2016;24:862\u201371.","journal-title":"Trends Microbiol"},{"key":"221_CR12","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.febslet.2011.04.054","volume":"585","author":"J-M Bolla","year":"2011","unstructured":"Bolla J-M, et al. Strategies for bypassing the membrane barrier in multidrug resistant gram-negative bacteria. FEBS Lett. 2011;585:1682\u201390.","journal-title":"FEBS Lett"},{"key":"221_CR13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/anie.201508330","volume":"55","author":"BK Gorityala","year":"2016","unstructured":"Gorityala BK, et al. Adjuvants based on hybrid antibiotics overcome resistance in pseudomonas aeruginosa and enhance fluoroquinolone efficacy. Angew Chem\u2014Int Ed. 2016;55:555\u20139.","journal-title":"Angew Chem\u2014Int Ed"},{"key":"221_CR14","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1021\/acs.jmedchem.6b01742","volume":"60","author":"Y Lyu","year":"2017","unstructured":"Lyu Y, et al. Amphiphilic tobramycin\u2013lysine conjugates sensitize multidrug resistant gram-negative bacteria to rifampicin and minocycline. J Med Chem. 2017;60:3684\u2013702.","journal-title":"J Med Chem"},{"issue":"9","key":"221_CR15","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1093\/jac\/dkz228","volume":"74","author":"Temilolu Idowu","year":"2019","unstructured":"Idowu T, Ammeter D, Arthur G, Zhanel GG, Schweizer F. Potentiation of \u03b2-lactam antibiotics and \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against multidrug and extensively drug-resistant pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates. J Antimicrob Chemother. In press 2019; \n                    https:\/\/doi.org\/10.1093\/jac\/dkz228\n                    \n                  .","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"221_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1440-1681.1979.tb01253.x","volume":"6","author":"PJ Chiu","year":"1979","unstructured":"Chiu PJ, Miller GH, Long JF, Waitz JA. Renal uptake and nephrotoxicity of gentamicin during urinary alkalinization in rats. Clin Exp Pharm Physiol. 1979;6:317\u201326.","journal-title":"Clin Exp Pharm Physiol"},{"key":"221_CR17","doi-asserted-by":"publisher","first-page":"5917","DOI":"10.1021\/acs.jmedchem.6b00432","volume":"59","author":"M Yu","year":"2016","unstructured":"Yu M, et al. Nontoxic metal\u2013cyclam complexes, a new class of compounds with potency against drug-resistant Mycobacterium tuberculosis. J Med Chem. 2016;59:5917\u201321.","journal-title":"J Med Chem"},{"key":"221_CR18","doi-asserted-by":"publisher","first-page":"8761","DOI":"10.1074\/jbc.M312080200","volume":"279","author":"K Perron","year":"2004","unstructured":"Perron K, et al. CzcR-CzcS, a two-component system involved in heavy metal and carbapenem resistance in Pseudomonas aeruginosa. J Biol Chem. 2004;279:8761\u20138.","journal-title":"J Biol Chem"},{"key":"221_CR19","doi-asserted-by":"publisher","first-page":"9724","DOI":"10.1021\/acs.jmedchem.7b01198","volume":"60","author":"T Idowu","year":"2017","unstructured":"Idowu T, Samadder P, Arthur G, Schweizer F. Amphiphilic modulation of glycosylated antitumor ether lipids results in a potent triamino scaffold against epithelial cancer cell lines and BT474 cancer stem cells. J Med Chem. 2017;60:9724\u201338.","journal-title":"J Med Chem"},{"key":"221_CR20","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1128\/AAC.01538-07","volume":"52","author":"GG Zhanel","year":"2008","unstructured":"Zhanel GG, et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother. 2008;52:1430\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"221_CR21","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1128\/AAC.00469-10","volume":"54","author":"GG Zhanel","year":"2010","unstructured":"Zhanel GG, et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother. 2010;54:4684\u201393.","journal-title":"Antimicrob Agents Chemother"},{"key":"221_CR22","doi-asserted-by":"publisher","first-page":"i7","DOI":"10.1093\/jac\/dkt022","volume":"68","author":"GG Zhanel","year":"2013","unstructured":"Zhanel GG, et al. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. J Antimicrob Chemother. 2013;68:i7\u201322.","journal-title":"J Antimicrob Chemother"},{"key":"221_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"221_CR24","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. In: CLSI Supplement M100. 27th Ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2017."},{"key":"221_CR25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1128\/JCM.43.1.140-143.2005","volume":"43","author":"G Orhan","year":"2005","unstructured":"Orhan G, Bayram A, Zer Y, Balci I. Synergy tests by e test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J Clin Microbiol. 2005;43:140\u20133.","journal-title":"J Clin Microbiol"},{"key":"221_CR26","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1128\/AAC.00999-09","volume":"54","author":"J Meletiadis","year":"2010","unstructured":"Meletiadis J, Pournaras S, Roilides E, Walsh TJ. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, monte carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother. 2010;54:602\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"221_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.chemphyslip.2015.07.003","volume":"194","author":"T Idowu","year":"2016","unstructured":"Idowu T, Samadder P, Arthur G, Schweizer F. Design, synthesis and antitumor properties of glycosylated antitumor ether lipid (GAEL)-chlorambucil-hybrids. Chem Phys Lipids. 2016;194:139\u201348.","journal-title":"Chem Phys Lipids"},{"key":"221_CR28","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1002\/chem.201406404","volume":"21","author":"Y Berkov-Zrihen","year":"2015","unstructured":"Berkov-Zrihen Y, et al. Tobramycin and nebramine as pseudo-oligosaccharide scaffolds for the development of antimicrobial cationic amphiphiles. Chem\u2014Eur J. 2015;21:4340\u20139.","journal-title":"Chem\u2014Eur J"},{"key":"221_CR29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1586\/eri.12.25","volume":"10","author":"GG Zhanel","year":"2012","unstructured":"Zhanel GG, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Exp Rev Anti Infect Ther. 2012;10:459\u201373.","journal-title":"Exp Rev Anti Infect Ther"},{"key":"221_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejmech.2019.04.034","volume":"174","author":"T Idowu","year":"2019","unstructured":"Idowu T, Arthur G, Zhanel GG, Schweizer F. Heterodimeric rifampicin\u2013tobramycin conjugates break intrinsic resistance of Pseudomonas aeruginosa to doxycycline and chloramphenicol in vitro and in a Galleria mellonella in vivo model. Eur J Med Chem. 2019;174:16\u201332.","journal-title":"Eur J Med Chem"},{"key":"221_CR31","first-page":"e01045","volume":"61","author":"HS Sader","year":"2017","unstructured":"Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK. Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016. Antimicrob Agents Chemother. 2017;61:e01045\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"221_CR32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","volume":"77","author":"D Wong","year":"2017","unstructured":"Wong D, van Duin D. Novel beta-lactamase inhibitors: unlocking their potential in therapy. Drugs . 2017;77:615\u201328.","journal-title":"Drugs"},{"key":"221_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3109\/03009734.2014.899279","volume":"119","author":"T T\u00e4ngd\u00e9n","year":"2014","unstructured":"T\u00e4ngd\u00e9n T. Combination antibiotic therapy for multidrug-resistant gram-negative bacteria. UPS J Med Sci. 2014;119:149\u201353.","journal-title":"UPS J Med Sci"},{"key":"221_CR34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1128\/CMR.05041-11","volume":"25","author":"PD Tamma","year":"2012","unstructured":"Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25:450\u201370.","journal-title":"Clin Microbiol Rev"},{"key":"221_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","volume":"17","author":"M Tyers","year":"2019","unstructured":"Tyers M, Wright GD. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat Rev Microbiol. 2019;17:141\u201355.","journal-title":"Nat Rev Microbiol"},{"key":"221_CR36","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1128\/MMBR.67.4.593-656.2003","volume":"67","author":"H Nikaido","year":"2003","unstructured":"Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003;67:593\u2013656.","journal-title":"Microbiol Mol Biol Rev"},{"key":"221_CR37","first-page":"2602","volume":"7","author":"H Singh","year":"2013","unstructured":"Singh H, Thangaraj P, Chakrabarti A. Acinetobacter baumannii: a brief account of mechanisms of multidrug resistance and current and future therapeutic management. J Clin Diagn Res. 2013;7:2602\u20135.","journal-title":"J Clin Diagn Res"},{"key":"221_CR38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0163-7258(85)90069-5","volume":"27","author":"H Nikaido","year":"1985","unstructured":"Nikaido H. Role of permeability barriers in resistance to \u03b2-lactam antibiotics. Pharm Ther. 1985;27:197\u2013231.","journal-title":"Pharm Ther"},{"key":"221_CR39","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1128\/AAC.00682-15","volume":"59","author":"M Berditsch","year":"2015","unstructured":"Berditsch M, et al. Synergistic effect of membrane-active peptides polymyxin B and gramicidin S on multidrug-resistant strains and biofilms of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2015;59:5288\u201396.","journal-title":"Antimicrob Agents Chemother"},{"key":"221_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11892-9","volume":"7","author":"G Rampioni","year":"2017","unstructured":"Rampioni G, et al. Effect of efflux pump inhibition on Pseudomonas aeruginosa transcriptome and virulence. Sci Rep. 2017;7:11392.","journal-title":"Sci Rep"},{"key":"221_CR41","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1021\/acs.jmedchem.7b00156","volume":"60","author":"X Yang","year":"2017","unstructured":"Yang X, et al. A tobramycin vector enhances synergy and efficacy of efflux pump inhibitors against multidrug-resistant gram-negative bacteria. J Med Chem. 2017;60:3913\u201332.","journal-title":"J Med Chem"},{"key":"221_CR42","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1128\/AAC.01009-09","volume":"54","author":"K Bush","year":"2010","unstructured":"Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54:969\u201376.","journal-title":"Antimicrob Agents Chemother"},{"key":"221_CR43","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1093\/jac\/dkv131","volume":"70","author":"SD Lahiri","year":"2015","unstructured":"Lahiri SD, et al. Selection and molecular characterization of ceftazidime\/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. J Antimicrob Chemother. 2015;70:1650\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"221_CR44","first-page":"3322","volume":"73","author":"G Cabot","year":"2018","unstructured":"Cabot G, Florit-Mendoza L, S\u00e1nchez-Diener I, Zamorano L, Oliver A. Deciphering \u03b2-lactamase-independent \u03b2-lactam resistance evolution trajectories in Pseudomonas aeruginosa. J Antimicrob Chemother. 2018;73:3322\u201331.","journal-title":"J Antimicrob Chemother"},{"key":"221_CR45","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/jac\/24.suppl_A.239","volume":"24","author":"A Ferrara","year":"1989","unstructured":"Ferrara A, Grassi FA, Grassi G, Piccioni PD, Grassi GG. Bactericidal activity of meropenem and interactions with other antibiotics. J Antimicrob Chemother. 1989;24:239\u201350.","journal-title":"J Antimicrob Chemother"},{"key":"221_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jcf.2006.05.015","volume":"6","author":"KP Coulthard","year":"2007","unstructured":"Coulthard KP, et al. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis\u2014caution with trough concentrations. J Cyst Fibros. 2007;6:125\u201330.","journal-title":"J Cyst Fibros"},{"key":"221_CR47","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/jac\/dkm377","volume":"60","author":"L Leibovici","year":"2007","unstructured":"Leibovici L, Paul M. Aminoglycoside\/B-lactam combinations in clinical practice. J Antimicrob Chemother. 2007;60:911\u20132.","journal-title":"J Antimicrob Chemother"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41429-019-0221-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41429-019-0221-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41429-019-0221-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:32:16Z","timestamp":1684618336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-019-0221-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,16]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["221"],"URL":"https:\/\/doi.org\/10.1038\/s41429-019-0221-9","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,16]]},"assertion":[{"value":"8 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}